Understanding and treating Polycystic Ovary Syndrome
Multidisciplinary Combined Precise Diagnosis and Treatment of Polycystic Ovary Syndrome
Shanghai 10th People's Hospital · NCT06047574
This study is trying to gather information from women with polycystic ovary syndrome to find new ways to understand and treat their condition better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | Female |
| Sponsor | Shanghai 10th People's Hospital (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06047574 on ClinicalTrials.gov |
What this trial studies
This observational study collects clinical data and serum samples from women with polycystic ovary syndrome (PCOS) to analyze various factors such as body measurements, skin conditions, diet, and hormonal levels. Using statistical software and experimental techniques, the study aims to identify new biomarkers and explore the mechanisms behind PCOS. The goal is to create a comprehensive clinical research database that supports personalized medicine approaches for PCOS management.
Who should consider this trial
Good fit: Ideal candidates for this study are females aged 18 to 45 diagnosed with polycystic ovary syndrome.
Not a fit: Patients outside the age range of 18 to 45 or those with specific hormonal disorders or severe systemic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and personalized treatment options for women suffering from PCOS.
How similar studies have performed: Other studies have shown promise in identifying biomarkers and understanding PCOS, but this multidisciplinary approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female aged 18- 45; Exclusion Criteria: * Female patients younger than 18 years old or older than 45 years old; * Ovulatory disorders caused by premature ovarian failure, pituitary amenorrhea, hypothalamic amenorrhea, and thyroid dysfunction; * Congenital adrenal hyperplasia, reservoir Hin syndrome, hyperprolactinemia, adrenal tumors and other diseases that cause hyperandrogenism; * Abnormal liver or renal function((≥ 3 times of the upper limit of normal range) * Type 1 diabetes, single gene mutation diabetes, or pancreatic damage Diabetes or other secondary diabetes caused by diabetes; * History of malignant tumors; * Severe infection, severe anemia, neutropenia and other systemic chronic diseases; * Undergo total hysterectomy or ovarian adnexectomy; * Mental illness, dementia or other cognitive behavioral problems; * Use hypoglycemic drugs that may affect insulin resistance and androgen levels in the last 3 months, including thiazolidinediones, metformin, SGLT-2, and acarbose and GLP-1RA and other drugs; * Use letrozole, clomiphene, oral contraceptives, glucocorticoids, gonadotropins, gonadotropin-releasing hormone agonists, anti-androgens (spironolactone, Cyproterone acetate, flutamide, etc.) and other drugs for the treatment of PCOS.
Where this trial is running
Shanghai, Shanghai Municipality
- Department of Endocrinology, Shanghai Tenth People's Hospital — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Manna Zhang, Dr
- Email: mannazhang@126.com
- Phone: 86-21-66301004
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Polycystic Ovary Syndrome, Clinical characteristics, New biomarkers, Multidisciplinary